产房中缩宫素应用的精细化管理与风险管控OA
Refined management and risk control in the use of oxytocin in delivery rooms
缩宫素作为产房中催引产的关键药物,在促进子宫收缩方面发挥着重要作用,但其使用需要精细化管理以确保母儿安全,避免子宫过度收缩及相关并发症的发生.文章系统综述了缩宫素的生理药理机制、不同给药方案的临床效果、监测技术、风险因素及其管控策略,结合最新的随机对照试验和观察性研究,重点探讨了缩宫素剂量调控、使用时机、个体化管理及多学科协作在降低剖宫产率、预防子宫破裂和产后出血中的应用价值.通过综合分析现有证据,文章旨在为产科临床实践提供循证指导,以促进缩宫素的安全有效使用,优化产房管理流程,提高母儿健康结局.
Oxytocin plays a crucial role in the process of labor induction and augmentation by promoting uterine contractions.However,its administration requires refined management to ensure maternal and fetal safety and to avoid uterine tachysystole and related complications.This article systematically reviews the physiological and pharmacological mechanisms of oxytocin,clinical outcomes of different administration protocols,monitoring techniques,risk factors and corresponding control strategies.Incorporating the latest randomized controlled trials and observational studies,it focuses on the clinical value of oxytocin dose adjustment,timing of use,individualized management,and multidisciplinary collaboration in reducing cesarean section rates and preventing uterine rupture and postpartum hemorrhage.Through a comprehensive analysis of existing evidence,this paper aims to provide evidence-based guidance for clinical obstetric practice,promote the safe and effective use of oxytocin,optimize delivery room management protocols,and improve maternal and neonatal health outcomes.
金志珊;赵茵
华中科技大学同济医学院附属协和医院妇产科,湖北武汉 430022华中科技大学同济医学院附属协和医院妇产科,湖北武汉 430022||深圳华中科技大学研究院,广东 深圳 518000
医药卫生
缩宫素产房管理风险管控剖宫产子宫破裂产后出血
oxytocindelivery room managementrisk controlcesarean sectionuterine rupturepostpartum hemorrhage
《中国实用妇科与产科杂志》 2026 (4)
389-395,7
National Natural Science Foundation of China(82171678)Shenzhen Basic Research Special Project(Natural Science Foundation)(JCYJ20230807143504009) 国家自然科学基金(82171678)深圳市基础研究专项(自然科学基金)(JCYJ20230807143504009)
评论